B-cell hyperactivity in primary Sjögren's syndrome

Expert Review of Clinical Immunology

Volumn 10, Issue 4, 2014, Pages 483-499

  Kroese, Frans G M ^a   Abdulahad, Wayel H ^a   Haacke, Erlin ^a   Bos, Nicolaas A ^a   Vissink, Arjan ^a   Bootsma, Hendrika ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

autoantibodies; autoimmunity; B cells; chemokines; cytokines; pathogenesis; primary Sj grens syndrome; salivary gland

Indexed keywords

B CELL ACTIVATING FACTOR; B LYMPHOCYTE RECEPTOR; CD40 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 6; INTRINSIC B CELL FACTOR; INTRINSIC FACTOR; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

B CELL HYPERACTIVITY; B LYMPHOCYTE ACTIVATION; CELL DIFFERENTIATION; CELL EXPANSION; CELL GROWTH; CELL INFILTRATION; CELL PROLIFERATION; CELL SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOPATHOGENESIS; LYMPHOID CELL; LYMPHOID TISSUE; NONHUMAN; PROTEIN FUNCTION; REVIEW; SJOEGREN SYNDROME; T LYMPHOCYTE; TH17 CELL;

AUTOANTIBODIES; B-LYMPHOCYTES; CYTOKINES; HUMANS; LYMPHOCYTE ACTIVATION; SJOGREN'S SYNDROME;

EID: 84896961753     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.891439     Document Type: Review

References (165)

1. Fox RI. Sjogren's syndrome. Lancet 2005; 366(9482):321-31
2. Voulgarelis M, Tzioufas AG. Pathogenetic mechanisms in the initiation and perpetuation of Sjogren's syndrome. Nat Rev Rheumatol 2010;6(9):529-37
3. Hjelmervik TO, Petersen K, Jonassen I, et al. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum 2005; 52(5):1534-44
4. Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 2006; 103(8):2770-5
5. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, et al. Systemic increase in type I interferon activity in Sjogren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol 2008;38(7): 2024-33
6. Lessard CJ, Li H, Adrianto I, et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren's syndrome. Nat Genet 2013;45(11):1284-92
7. Igoe A, Scofield RH. Autoimmunity and infection in Sjogren's syndrome. Curr Opin Rheumatol 2013;25(4):480-7
8. Inoue H, Mishima K, Yamamoto-Yoshida S, et al. Aryl hydrocarbon receptor-mediated induction of EBV reactivation as a risk factor for Sjogren's syndrome. J Immunol 2012; 188(9):4654-62
9. Routsias JG, Tzioufas AG. B-cell epitopes of the intracellular autoantigens Ro/SSA and La/SSB: tools to study the regulation of the autoimmune response. J Autoimmun 2010; 35(3):256-64
10. Manoussakis MN, Kapsogeorgou EK. The role of intrinsic epithelial activation in the pathogenesis of Sjogren's syndrome. J Autoimmun 2010;35(3):219-24
11. Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjogren's syndrome. Nat Rev Rheumatol 2013;9(9):544-56
12. Moerman RV, Arends S, Meiners PM, et al. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann Rheum Dis 2014;73(2):472-4
13. Rawlings DJ, Schwartz MA, Jackson SW, Meyer-Bahlburg A. Integration of B cell responses through Toll-like receptors and antigen receptors. Nat Rev Immunol 2012; 12(4):282-94
14. Kil LP, Hendriks RW. Aberrant B cell selection and activation in systemic lupus erythematosus. Int Rev Immunol 2013; 32(4):445-70
15. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjogren's syndrome. J Autoimmun 2010;34(4):400-7
16. Pijpe J, Meijer JM, Bootsma H, et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjogren's syndrome. Arthritis Rheum 2009;60(11):3251-6
17. Szyszko EA, Brokstad KA, Oijordsbakken G, et al. Salivary glands of primary Sjogren's syndrome patients express factors vital for plasma cell survival. Arthritis Res Ther 2011; 13(1):R2
18. Mitsias DI, Tzioufas AG, Veiopoulou C, et al. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin Exp Immunol 2002;128(3): 562-8
19. Horvath S, Nazmul-Hossain AN, Pollard RP, et al. Systems analysis of primary Sjogren's syndrome pathogenesis in salivary glands identifies shared pathways in human and a mouse model. Arthritis Res Ther 2012;14(6):R238
20. Hernandez-Molina G, Michel-Peregrina M, Hernandez-Ramirez DF, et al. Chemokine saliva levels in patients with primary Sjogren's syndrome, associated Sjogren's syndrome, pre-clinical Sjogren's syndrome and systemic autoimmune diseases. Rheumatology (Oxford) 2011;50(7): 1288-92
21. Lee YJ, Scofield RH, Hyon JY, et al. Salivary chemokine levels in patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2010;49(9):1747-52
22. Yeruva S, Ramadori G, Raddatz D. NF-kappaB-dependent synergistic regulation of CXCL10 gene expression by IL-1beta and IFN-gamma in human intestinal epithelial cell lines. Int J Colorectal Dis 2008;23(3):305-17
23. Ogawa N, Ping L, Zhenjun L, et al. Involvement of the interferon-gammainduced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjogren's syndrome. Arthritis Rheum 2002;46(10): 2730-41
24. Roescher N, Tak PP, Illei GG. Cytokines in Sjogren's syndrome. Oral Dis 2009;15(8): 519-26
25. Muehlinghaus G, Cigliano L, Huehn S, et al. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood 2005;105(10):3965-71
26. Amft N, Curnow SJ, Scheel-Toellner D, et al. Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjogren's syndrome. Arthritis Rheum 2001;44(11): 2633-41
27. Vanbervliet B, Bendriss-Vermare N, Massacrier C, et al. The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J Exp Med 2003;198(5):823-30
28. Bave U, Nordmark G, Lovgren T, et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005;52(4):1185-95
29. Corsiero E, Bombardieri M, Manzo A, et al. Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases. Immunol Lett 2012;145(1-2):62-7
30. Barone F, Bombardieri M, Manzo A, et al. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogren's syndrome. Arthritis Rheum 2005; 52(6):1773-84
31. Barone F, Bombardieri M, Rosado MM, et al. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol 2008;180(7): 5130-40
32. Xanthou G, Polihronis M, Tzioufas AG, et al. "Lymphoid" chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjogren's syndrome patients: possible participation in lymphoid structure formation. Arthritis Rheum 2001;44(2): 408-18
33. Rangel-Moreno J, Carragher DM, de la Luz Garcia-Hernandez M, et al. The development of inducible bronchusassociated lymphoid tissue depends on IL-17. Nat Immunol 2011;12(7):639-46
34. Peters A, Pitcher LA, Sullivan JM, et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 2011;35(6):986-96
35. Chen Z, O'Shea JJ. Th17 cells: a new fate for differentiating helper T cells. Immunol Res 2008;41(2):87-102
36. Grogan JL, Ouyang W. A role for Th17 cells in the regulation of tertiary lymphoid follicles. Eur J Immunol 2012; 42(9):2255-62
37. Lim HW, Lee J, Hillsamer P, Kim CH. Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3+ regulatory T cells. J Immunol 2008;180(1):122-9
38. Katsifis GE, Rekka S, Moutsopoulos NM, et al. Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome immunopathogenesis. Am J Pathol 2009;175(3):1167-77
39. Sakai A, Sugawara Y, Kuroishi T, et al. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjogren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 2008;181(4):2898-906
40. Ciccia F, Guggino G, Rizzo A, et al. Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren's syndrome. Ann Rheum Dis 2012;71(2): 295-301
41. Salomonsson S, Larsson P, Tengner P, et al. Expression of the B cell-attracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease Sjogren's syndrome. Scand J Immunol 2002;55(4):336-42
42. Salomonsson S, Jonsson MV, Skarstein K, et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum 2003;48(11):3187-201
43. Kramer JM, Klimatcheva E, Rothstein TL. CXCL13 is elevated in Sjogren's syndrome in mice and humans and is implicated in disease pathogenesis. J Leukoc Biol 2013; 94(5):1079-89
44. Badr G, Borhis G, Lefevre EA, et al. BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells. Blood 2008;111(5):2744-54
45. Hansen A, Lipsky PE, Dorner T. B cells in Sjogren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ther 2007;9(4):218
46. Hansen A, Odendahl M, Reiter K, et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2002;46(8): 2160-71
47. Hansen A, Reiter K, Ziprian T, et al. Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sjogren's syndrome. Arthritis Rheum 2005;52(7):2109-19
48. Risselada AP, Looije MF, Kruize AA, et al. The role of ectopic germinal centers in the immunopathology of primary Sjogren's syndrome: a systematic review. Semin Arthritis Rheum 2013;42(4):368-76
49. Jonsson MV, Skarstein K, Jonsson R, Brun JG. Serological implications of germinal center-like structures in primary Sjogren's syndrome. J Rheumatol 2007; 34(10):2044-9
50. Le Pottier L, Devauchelle V, Fautrel A, et al. Ectopic germinal centers are rare in Sjogren's syndrome salivary glands and do not exclude autoreactive B cells. J Immunol 2009;182(6):3540-7
51. Theander E, Vasaitis L, Baecklund E, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann Rheum Dis 2011;70(8):1363-8
52. Allen CD, Ansel KM, Low C, et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol 2004;5(9):943-52
53. Bombardieri M, Barone F, Humby F, et al. Activation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjogren's syndrome. J Immunol 2007;179(7):4929-38
54. Stott DI, Hiepe F, Hummel M, et al. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren's syndrome. J Clin Invest 1998; 102(5):938-46
55. Zuckerman NS, Hazanov H, Barak M, et al. Somatic hypermutation and antigen-driven selection of B cells are altered in autoimmune diseases. J Autoimmun 2010;35(4):325-35
56. Kaschner S, Hansen A, Jacobi A, et al. Immunoglobulin Vlambda light chain gene usage in patients with Sjogren's syndrome. Arthritis Rheum 2001;44(11):2620-32
57. Hamza N, Bootsma H, Yuvaraj S, et al. Persistence of immunoglobulin- producing cells in parotid salivary glands of patients with primary Sjogren's syndrome after B cell depletion therapy. Ann Rheum Dis 2012;71(11):1881-7
58. Vinuesa CG, Sanz I, Cook MC. Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol 2009;9(12):845-57
59. Tengner P, Halse AK, Haga HJ, et al. Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sjogren's syndrome. Arthritis Rheum 1998;41(12): 2238-48
60. Halse A, Harley JB, Kroneld U, Jonsson R. Ro/SS-A-reactive B lymphocytes in salivary glands and peripheral blood of patients with Sjogren's syndrome. Clin Exp Immunol 1999;115(1):203-7
61. Aqrawi LA, Skarstein K, Oijordsbakken G, Brokstad KA. Ro52- and Ro60-specific B cell pattern in the salivary glands of patients with primary Sjogren's syndrome. Clin Exp Immunol 2013;172(2):228-37
62. Aqrawi LA, Brokstad KA, Jakobsen K, et al. Low number of memory B cells in the salivary glands of patients with primary Sjogren's syndrome. Autoimmunity 2012; 45(7):547-55
63. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009;9(7):491-502
64. Lahiri A, Pochard P, Le Pottier L, et al. The complexity of the BAFF TNF-family members: implications for autoimmunity. J Autoimmun 2012;39(3):189-98
65. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002; 109(1):59-68
66. Pers JO, D'Arbonneau F, Devauchelle-Pensec V, et al. Is periodontal disease mediated by salivary BAFF in Sjogren's syndrome? Arthritis Rheum 2005; 52(8):2411-14
67. Jonsson MV, Szodoray P, Jellestad S, et al. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J Clin Immunol 2005;25(3):189-201
68. Pollard RP, Abdulahad WH, Vissink A, et al. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial. Ann Rheum Dis 2013;72(1): 146-8
69. Pers JO, Daridon C, Devauchelle V, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005;1050:34-9
70. Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003;62(2): 168-71
71. Daridon C, Devauchelle V, Hutin P, et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum 2007;56(4): 1134-44
72. Lavie F, Miceli-Richard C, Quillard J, et al. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J Pathol 2004;202(4):496-502
73. Ittah M, Miceli-Richard C, Eric Gottenberg J, et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 2006;8(2):R51
74. Ittah M, Miceli-Richard C, Gottenberg JE, et al. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways. Eur J Immunol 2008;38(4):1058-64
75. Brkic Z,Maria NI, vanHelden-Meeuwsen CG, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 2013;72(5): 728-35
76. Lavie F, Miceli-Richard C, Ittah M, et al. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjogren's syndrome. Scand J Immunol 2008;67(2):185-92
77. Yoshimoto K, Tanaka M, Kojima M, et al. Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjogren's syndrome. Arthritis Res Ther 2011;13(5): R170
78. Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007;179(11): 7276-86
79. Liu Z, Davidson A. BAFF and selection of autoreactive B cells. Trends Immunol 2011; 32(8):388-94
80. Abu-Rish EY, Amrani Y, Browning MJ. Toll-like receptor 9 activation induces expression of membrane-bound B-cell activating factor (BAFF) on human B cells and leads to increased proliferation in response to both soluble and membrane-bound BAFF. Rheumatology (Oxford) 2013;52(7):1190-201
81. He B, Santamaria R, Xu W, et al. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol 2010;11(9):836-45
82. Ozcan E, Rauter I, Garibyan L, et al. Toll-like receptor 9, transmembrane activator and calcium-modulating cyclophilin ligand interactor, and CD40 synergize in causing B-cell activation. J Allergy Clin Immunol 2011;128(3):601-9. e1-4
83. Chu VT, Berek C. Immunization induces activation of bone marrow eosinophils required for plasma cell survival. Eur J Immunol 2012;42(1):130-7
84. Braun D, Caramalho I, Demengeot J. IFNalpha/ beta enhances BCR-dependent B cell responses. Int Immunol 2002;14(4):411-19
85. Fairfax KA, Kallies A, Nutt SL, Tarlinton DM. Plasma cell development: from B-cell subsets to long-term survival niches. Semin Immunol 2008;20(1):49-58
86. Xu W, Joo H, Clayton S, et al. Macrophages induce differentiation of plasma cells through CXCL10/IP-10. J Exp Med 2012;209(10):1813-23.S1-2
87. Konforte D, Simard N, Paige CJ. IL-21: an executor of B cell fate. J Immunol 2009; 182(4):1781-7
88. Ettinger R, Sims GP, Fairhurst AM, et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 2005;175(12):7867-79
89. Bryant VL, Ma CS, Avery DT, et al. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5+ T follicular helper cells. J Immunol 2007;179(12):8180-90
90. Ding BB, Bi E, Chen H, et al. IL-21 and CD40L synergistically promote plasma cell differentiation through upregulation of Blimp-1 in human B cells. J Immunol 2013;190(4):1827-36
91. Ettinger R, Sims GP, Robbins R, et al. IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol 2007;178(5): 2872-82
92. Guerrier T, Youinou P, Pers JO, Jamin C. TLR9 drives the development of transitional B cells towards the marginal zone pathway and promotes autoimmunity. J Autoimmun 2012;39(3):173-9
93. Daridon C, Pers JO, Devauchelle V, et al. Identification of transitional type II B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2006; 54(7):2280-8
94. Kang KY, Kim HO, Kwok SK, et al. Impact of interleukin-21 in the pathogenesis of primary Sjogren's syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands. Arthritis Res Ther 2011;13(5):R179
95. Maehara T, Moriyama M, Hayashida JN, et al. Selective localization of T helper subsets in labial salivary glands from primary Sjogren's syndrome patients. Clin Exp Immunol 2012;169(2):89-99
96. Tangye SG, Ma CS, Brink R, Deenick EK. The good, the bad and the ugly - TFH cells in human health and disease. Nat Rev Immunol 2013;13(6):412-26
97. Szabo K, Papp G, Barath S, et al. Follicular helper T cells may play an important role in the severity of primary Sjogren's syndrome. Clin Immunol 2013;147(2):95-104
98. Ma CS, Deenick EK, Batten M, Tangye SG. The origins, function, and regulation of T follicular helper cells. J Exp Med 2012; 209(7):1241-53
99. Diehl SA, Schmidlin H, Nagasawa M, et al. IL-6 triggers IL-21 production by human CD4+ T cells to drive STAT3-dependent plasma cell differentiation in B cells. Immunol Cell Biol 2012;90(8):802-11
100. Carbone G, Wilson A, Diehl SA, et al. Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis. Int J Biol Sci 2013;9(3):279-88
101. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008;14(3):109-19
102. Szodoray P, Alex P, Brun JG, et al. Circulating cytokines in primary Sjogren's syndrome determined by a multiplex cytokine array system. Scand J Immunol 2004;59(6):592-9
103. Pollard RP, Abdulahad WH, Bootsma H, et al. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome. Ann Rheum Dis 2013;72(12): 2028-50
104. Fox RI, Kang HI, Ando D, et al. Cytokine mRNA expression in salivary gland biopsies of Sjogren's syndrome. J Immunol 1994; 152(11):5532-9
105. Lee SY, Han SJ, Nam SM, et al. Analysis of tear cytokines and clinical correlations in Sjogren syndrome dry eye patients and non-Sjogren syndrome dry eye patients. Am J Ophthalmol 2013;156(2):247-53.e1
106. Daridon C, Guerrier T, Devauchelle V, et al. Polarization of B effector cells in Sjogren's syndrome. Autoimmun Rev 2007; 6(7):427-31
107. Hiepe F, Dorner T, Hauser AE, et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 2011;7(3):170-8
108. Chu VT, Berek C. The establishment of the plasma cell survival niche in the bone marrow. Immunol Rev 2013;251(1):177-88
109. Gellrich S, Rutz S, Borkowski A, et al. Analysis of V(H)-D-J(H) gene transcripts in B cells infiltrating the salivary glands and lymph node tissues of patients with Sjogren's syndrome. Arthritis Rheum 1999; 42(2):240-7
110. Hansen A, Gosemann M, Pruss A, et al. Abnormalities in peripheral B cell memory of patients with primary Sjogren's syndrome. Arthritis Rheum 2004;50(6): 1897-908
111. Routsias JG, Goules JD, Charalampakis G, et al. Malignant lymphoma in primary Sjogren's syndrome: an update on the pathogenesis and treatment. Semin Arthritis Rheum 2013;43(2):178-86
112. Morse HC 3rd, Kearney JF, Isaacson PG, et al. Cells of the marginal zone-origins, function and neoplasia. Leuk Res 2001; 25:2):169-178
113. Silverman GJ, Goodyear CS. Confounding B-cell defences: lessons from a staphylococcal superantigen. Nat Rev Immunol 2006;6(6):465-75
114. Hamza N, Hersberg U, Kallenberg CG, et al. Immunoglobulin gene analysis reveals altered selective pressures on Ig-producing cells in parotid glands of primary Sjogren's syndrome patients; Submitted
115. Bohnhorst JO, Bjorgan MB, Thoen JE, et al. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J Immunol 2001;167(7):3610-18
116. Bohnhorst JO, Thoen JE, Natvig JB, Thompson KM. Significantly depressed percentage of CD27+ (memory) B cells among peripheral blood B cells in patients with primary Sjogren's syndrome. Scand J Immunol 2001;54(4):421-7
117. Abdulahad WH, Meijer JM, Kroese FG, et al. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjogren's syndrome: a double-blind, placebo-controlled study. Arthritis Rheum 2011;63(4):1116-23
118. Saadoun D, Terrier B, Bannock J, et al. Expansion of autoreactive unresponsive CD21-/low B cells in Sjogren's syndrome-associated lymphoproliferation. Arthritis Rheum 2013;65(4):1085-96
119. Bohnhorst JO, Bjorgan MB, Thoen JE, et al. Abnormal B cell differentiation in primary Sjogren's syndrome results in a depressed percentage of circulating memory B cells and elevated levels of soluble CD27 that correlate with Serum IgG concentration. Clin Immunol 2002;103(1): 79-88
120. Kato K, Chu P, Takahashi S, et al. Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Exp Hematol 2007;35(3): 434-42
121. Loenen WA, De Vries E, Gravestein LA, et al. The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis. Eur J Immunol 1992;22(2):447-55
122. Binard A, Le Pottier L, Devauchelle-Pensec V, et al. Is the blood B-cell subset profile diagnostic for Sjogren syndrome? Ann Rheum Dis 2009;68(9): 1447-52
123. d'Arbonneau F, Pers JO, Devauchelle V, et al. BAFF-induced changes in B cell antigen receptor-containing lipid rafts in Sjogren's syndrome. Arthritis Rheum 2006; 54(1):115-26
124. Pers JO, Youinou P. Are the B cells cast with the leading part in the Sjogren's syndrome scenario? Oral Dis 2013. [Epub ahead of print]
125. Tobon GJ, Renaudineau Y, Hillion S, et al. The Fms-like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 2010;62(11): 3447-56
126. Tobon GJ, Saraux A, Gottenberg JE, et al. Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 2013;65(12):3218-27
127. Kil LP, de Bruijn MJ, van Nimwegen M, et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood 2012; 119(16):3744-56
128. Nordmark G, Wang C, Vasaitis L, et al. Association of genes in the NF-kappaB pathway with antibody-positive primary Sjogren's syndrome. Scand J Immunol 2013;78(5):447-54
129. Nordmark G, Kristjansdottir G, Theander E, et al. Association of EBF1, FAM167A (C8orf13)-BLK and TNFSF4 gene variants with primary Sjogren's syndrome. Genes Immun 2011;12(2):100-9
130. Sun F, Li P, Chen H, et al. Association studies of TNFSF4, TNFAIP3 and FAM167A-BLK polymorphisms with primary Sjogren's syndrome in Han Chinese. J Hum Genet 2013;58(7):475-9
131. Cherukuri A, Cheng PC, Sohn HW, Pierce SK. The CD19/CD21 complex functions to prolong B cell antigen receptor signaling from lipid rafts. Immunity 2001; 14(2):169-79
132. Smith AJ, Gordon TP, Macardle PJ. Increased expression of the B-cell-regulatory molecule CD72 in primary Sjogren's syndrome. Tissue Antigens 2004;63(3): 255-9
133. Wu HJ, Bondada S. CD72, a coreceptor with both positive and negative effects on B lymphocyte development and function. J Clin Immunol 2009;29(1):12-21
134. Bournia VK, Vlachoyiannopoulos PG. Subgroups of Sjogren syndrome patients according to serological profiles. J Autoimmun 2012;39(1-2):15-26
135. Jonsson R, Theander E, Sjotrom B, et al. Autoantibodies present before symptom onset in primary Sjogren syndrome. JAMA 2013;310(17):1854-5
136. Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjogrens syndrome: a data-driven, expert consensus approach in the Sjogrens International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012;64(4):475-87
137. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61(6):554-8
138. Routsias JG, Tzioufas AG. Autoimmune response and target autoantigens in Sjogren's syndrome. Eur J Clin Invest 2010; 40(11):1026-36
139. Tzioufas AG, Kapsogeorgou EK, Moutsopoulos HM. Pathogenesis of Sjogren's syndrome: what we know and what we should learn. J Autoimmun 2012; 39(1-2):4-8
140. Lisi S, Sisto M, Lofrumento D, et al. Regulation of mRNA caspase-8 levels by anti-nuclear autoantibodies. Clin Exp Med 2010;10(3):199-203
141. Ronnblom L, Eloranta ML. The interferon signature in autoimmune diseases. Curr Opin Rheumatol 2013;25(2):248-53
142. Berggren O, Hagberg N, Weber G, et al. B lymphocytes enhance interferon-alpha production by plasmacytoid dendritic cells. Arthritis Rheum 2012;64(10):3409-19
143. Varin MM, Guerrier T, Devauchelle-Pensec V, et al. In Sjogren's syndrome, B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation. Autoimmun Rev 2012;11(4):252-8
144. Fillatreau S. Cytokine-producing B cells as regulators of pathogenic and protective immune responses. Ann Rheum Dis 2013; 72(Suppl 2):ii80-4
145. Luu VP, Vazquez MI, Zlotnik A. B cells participate in tolerance and autoimmunity through cytokine production. Autoimmunity 2014;47(1):1-12
146. Lund FE. Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 2008;20(3):332-8
147. Furuzawa-Carballeda J, Hernandez-Molina G, Lima G, et al. Peripheral regulatory cells immunophenotyping in Primary Sjogren's Syndrome: a cross-sectional study. Arthritis Res Ther 2013;15(3):R68
148. Hirotani M, Niino M, Fukazawa T, et al. Decreased IL-10 production mediated by Toll-like receptor 9 in B cells in multiple sclerosis. J Neuroimmunol 2010;221(1-2): 95-100
149. Barr TA, Shen P, Brown S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012;209(5):1001-10
150. Jenks SA, Sanz I. Altered B cell receptor signaling in human systemic lupus erythematosus. Autoimmun Rev 2009;8(3): 209-13
151. Shlomchik MJ. Activating systemic autoimmunity: B's, T's, and tolls. Curr Opin Immunol 2009;21(6):626-33
152. Green NM, Marshak-Rothstein A. Toll-like receptor driven B cell activation in the induction of systemic autoimmunity. Semin Immunol 2011;23(2):106-12
153. Zheng L, Zhang Z, Yu C, Yang C. Expression of Toll-like receptors 7, 8, and 9 in primary Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;109(6):844-50
154. Guerrier T, Le Pottier L, Devauchelle V, et al. Role of Toll-like receptors in primary Sjogren's syndrome with a special emphasis on B-cell maturation within exocrine tissues. J Autoimmun 2012;39(1-2):69-76
155. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62(4):960-8
156. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008;67(11):1541-4
157. Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013;72(6):1026-31
158. Adler S, Korner M, Forger F, et al. Evaluation of histological, serological and clinical changes in response to abatacept treatment of primary Sjogren's syndrome: a pilot study. Arthritis Care Res (Hoboken) 2013. [Epub ahead of print]
159. Meiners PM, Vissink A, Kroese FG, et al. Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (openlabel proof of concept ASAP study). Ann Rheum Dis Ann Rheum Dis 2014. [Epub ahead of print]
160. Puri KD, Di Paolo JA, Gold MR. B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies. Int Rev Immunol 2013; 32(4):397-427
161. Macauley MS, Pfrengle F, Rademacher C, et al. Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis. J Clin Invest 2013;123(7): 3074-83
162. Kroese FG, Bootsma H. Biomarkers: new biomarker for Sjogren's syndrome-time to treat patients. Nat Rev Rheumatol 2013; 9(10):570-2
163. Hammi AR, Al-Hashimi IH, Nunn ME, Zipp M. Assessment of SS-A and SS-B in parotid saliva of patients with Sjogren's syndrome. J Oral Pathol Med 2005;34(4): 198-203
164. Toker E, Yavuz S, Direskeneli H. Anti-Ro/ SSA and anti-La/SSB autoantibodies in the tear fluid of patients with Sjogren's syndrome. Br J Ophthalmol 2004;88(3): 384-7
165. Gottenberg JE, Seror R, Miceli-Richard C, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One 2013;8(5):e59868